OnKure Therapeutics (OKUR) Enterprise Value (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Enterprise Value came in at -$192.1 million in Q1 2026, down 98.66% YoY from -$14.3 billion in Q1 2025, and down 225.32% on a QoQ basis from -$59.0 million in Q4 2025.
OnKure Therapeutics (OKUR) Enterprise Value (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Enterprise Value data on file, last reported at -$192.1 million in Q1 2026.
- Quarterly Enterprise Value fell 98.66% year-over-year to -$192.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$192.1 million (down 98.66% YoY) and the FY2025 annual result came in at -$59.0 million, up 46.69% from the prior year.
- Enterprise Value slipped to -$192.1 million in Q1 2026, from -$59.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$59.0 million in Q4 2025 to a low of -$192.1 million in Q1 2026.
- A 5-year average of -$106.7 million and a median of -$101.2 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value soared 46.69% — and 2026, when it plunged 98.66%.
- Tracing OKUR's Enterprise Value over 5 years: stood at -$101.2 million in 2022, then decreased by 4.01% to -$105.2 million in 2023, then slipped by 5.26% to -$110.8 million in 2024, then soared by 46.69% to -$59.0 million in 2025, then slumped by 225.32% to -$192.1 million in 2026.
- The last three Enterprise Value figures came in at -$192.1 million (Q1 2026), -$59.0 million (Q4 2025), and -$70.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | -176.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -176.39 Mn |
| Mar 31, 2026 | -192.10 Mn |
| Dec 31, 2025 | -59.05 Mn |
| Sep 30, 2025 | -70.30 Mn |
| Jun 30, 2025 | -83.37 Mn |
| Mar 31, 2025 | -96.70 Mn |
| Dec 31, 2024 | -110.76 Mn |
| Sep 30, 2024 | -92.68 Mn |
| Jun 30, 2024 | -76.67 Mn |
| Mar 31, 2024 | -82.84 Mn |
| Dec 31, 2023 | -105.23 Mn |
| Sep 30, 2023 | -125.61 Mn |
| Jun 30, 2023 | -142.68 Mn |
| Mar 31, 2023 | -93.79 Mn |
| Dec 31, 2022 | -101.17 Mn |
| Sep 30, 2022 | -116.08 Mn |
| Jun 30, 2022 | -126.85 Mn |
| Mar 31, 2022 | -138.66 Mn |
| Dec 31, 2021 | -147.67 Mn |
| Sep 30, 2021 | -157.73 Mn |